Ipamorelin
A selective growth hormone secretagogue peptide that stimulates GH release from the pituitary with the highest selectivity of any GHRP - without raising cortisol, prolactin, or ACTH. The cleanest GH-stimulating peptide available, typically paired with a GHRH analogue (CJC-1295) for synergistic GH pulse amplification.
Reviewed & fact-checked by
Dr. Jane Smith, MD, PhDChief Medical Reviewer · Last updated: March 25, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Why Ipamorelin Is the Preferred GHRP
The GHRP (Growth Hormone Releasing Peptide) class includes several compounds: GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. All stimulate GH release, but with significantly different side effect profiles.
GHRP-2 and GHRP-6 elevate cortisol and prolactin alongside GH. Hexarelin desensitises receptors rapidly and strongly elevates cortisol. Ipamorelin is the exception: it produces selective GH stimulation without significant cortisol, prolactin, or ACTH elevation. This selectivity profile makes it the preferred choice for non-clinical use.
Mechanism of Action
Ipamorelin is a pentapeptide that mimics ghrelin (the hunger hormone) at the growth hormone secretagogue receptor (GHSR-1a) in the pituitary. Unlike ghrelin, which has broad systemic effects, Ipamorelin is highly selective for the pituitary GHSR with minimal cross-reactivity at other receptor types.
GHSR activation triggers GH release through IP3-mediated calcium mobilisation in somatotroph cells. The resulting GH pulse is physiologically normal in shape and duration - it mirrors the GH pulses that naturally occur during deep sleep, rather than producing the sustained supraphysiological GH elevation seen with exogenous HGH.
The Ipamorelin + CJC-1295 Protocol
The most established GHRP/GHRH combination. The rationale is straightforward:
- GHRH (mimicked by CJC-1295) tells the pituitary to prepare and release GH
- GHRP (Ipamorelin) tells the pituitary to amplify that release via GHSR activation
Activating both receptor pathways simultaneously produces synergistic GH pulse amplification 3-5x greater than either peptide alone. This is the biochemical basis for combining the two classes.
Standard protocol: 100-200mcg Ipamorelin + 100mcg CJC-1295 (no DAC), injected subcutaneously 30-60 minutes before sleep, fasted.
Sleep Timing Is Critical
Growth hormone is predominantly secreted during slow-wave sleep, with the largest pulse occurring in the first 90 minutes of sleep onset. Injecting Ipamorelin + CJC-1295 30-60 minutes before sleep amplifies this natural pulse at its physiologically correct timing - producing GH elevation during the sleep window when the body is already programmed to use it for tissue repair and cellular regeneration.
Stacking Interactions
How Ipamorelin interacts with other compounds
The standard GH optimisation stack. Inject both simultaneously before sleep. Most practitioners use 100-200mcg of each.
BPC-157 upregulates GH receptors in tissues. Ipamorelin increases circulating GH levels. BPC-157 makes target tissues more responsive to the GH that Ipamorelin produces.
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Active cancer or cancer history - GH promotes IGF-1 which is mitogenic
- ●Diabetic retinopathy
- ●Pregnancy
- ●Competitive athletes - WADA prohibited substance
Side Effects
- ●Mild water retention in first 2 weeks (resolves)
- ●Increased appetite - common and dose-dependent
- ●Mild headache in some users
- ●Flushing immediately post-injection
- ●Tingling or numbness (carpal tunnel symptoms) at high doses